Question explored with the scientific record
cholesterol
The short version: cholesterol is not one thing, and the "lower is always better" story is contradicted by the evidence in the elderly and the sick.
The retrieved studies show a real split. In middle-aged populations, higher LDL tracks with more heart attacks and strokes, and statins plus ezetimibe or PCSK9 inhibitors cut cardiovascular events by about 18% in a meta-analysis of over 100,000 patients [5]. But that same meta-analysis found no significant reduction in all-cause mortality [5]. A 2020 longitudinal study of 4,485 dyslipidemic patients found very low LDL was linked to nearly double the all-cause mortality risk, with no reduction in cardiovascular disease [2]. In heart failure patients, lower LDL was associated with higher death rates but no difference in ischemic events [4]. A systematic review found high LDL is inversely associated with mortality in most people over 60 [6]. A Japanese study of 173,539 people found the lowest mortality in the 200-239 mg/dL range, with the highest mortality below 160 [3].
The mechanism matters. The harm is not plain LDL; it is oxidized LDL, which macrophages take up through CD36 receptors to form foam cells [7][9]. That is why probucol, which prevents LDL oxidation without lowering cholesterol much, slowed atherosclerosis in rabbits [8]. The trials that show benefit are mostly industry-funded, and the surrogate endpoint problem is real: many studies measure LDL reduction, not death. The 2025 Korean cohort study showing ezetimibe benefit was observational, not randomized [10].
| Population | LDL finding | Mortality effect |
|---|---|---|
| Middle-aged, high LDL | Higher LDL, more heart events [1] | Statins reduce events, not death [5] |
| Dyslipidemic patients | Very low LDL | ~2x all-cause mortality [2] |
| Heart failure patients | LDL <100 mg/dL | Higher death, no fewer events [4] |
| Over 60 | Higher LDL | Lower mortality [6] |
| Japanese general population | 200-239 mg/dL | Lowest mortality [3] |
My call: for a middle-aged person with established heart disease, statins have real but modest benefit; for the elderly and the sick, aggressive LDL lowering may do more harm than good. Confidence: moderate.
Sources used 10
-
Extreme Nonfasting Remnant Cholesterol vs Extreme LDL Cholesterol as Contributors to Cardiovascular Disease and All-Cause Mortality in 90000 Individuals from the General Population
In the Copenhagen General Population Study, higher nonfasting remnant cholesterol and LDL cholesterol were associated with increased risks of IHD and MI, but remnant cholesterol was more strongly associated with all-cause mortality than LDL cholesterol.
DOI: 10.1373/clinchem.2014.234146 -
The association of repeatedly measured low-density lipoprotein cholesterol and all-cause mortality and cardiovascular disease in dyslipidemic patients: A longitudinal study
This longitudinal study evaluates the association between very low levels of low-density lipoprotein (LDL) cholesterol and all-cause mortality and cardiovascular disease in dyslipidemic patients, finding that very low LDL cholesterol is linked to increased all-cause mortality bu…
DOI: 10.1016/j.ijcard.2020.03.011 -
Blood Cholesterol as a Good Marker of Health in Japan
This study investigates the relationship between blood cholesterol levels and all-cause mortality in Japan, highlighting that higher cholesterol levels may not be a significant risk factor for mortality in the Japanese population.
DOI: 10.1159/000235712 -
LDL cholesterol and clinical outcomes in heart failure with reduced ejection fraction a competing risk analysis
This post-hoc analysis of the HF-ACTION trial in 1,274 adults with chronic stable HFrEF shows that lower baseline LDL-C (<100 mg/dL) is associated with higher all-cause mortality but not with ischemic cardiovascular events, suggesting that aggressive LDL-C lowering may not reduc…
DOI: 10.1038/s41598-025-24832-9 -
P5015Efficacy of lipid lowering therapy beyond statins to prevent cardiovascular events: A meta-analysis
In a meta-analysis of 9 randomized controlled trials including 100,610 patients, intensified lipid-lowering therapy with ezetimibe or PCSK9 inhibitors added to statins reduced cardiovascular events by 18%, myocardial infarction by 16%, and ischemic stroke by 23%, but did not sig…
DOI: 10.1093/eurheartj/ehz746.0193 -
Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review
This systematic review investigates the association between low-density lipoprotein cholesterol (LDL-C) and mortality in the elderly, finding that high LDL-C is inversely associated with mortality in most individuals over 60 years, challenging the traditional cholesterol hypothe…
DOI: 10.1136/bmjopen-2015-010401 -
Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation
The study shows that CD36 expression is transiently upregulated at both mRNA and protein levels during in vitro monocyte-to-macrophage differentiation, with a large intracellular pool of CD36 and M-CSF/soluble mediators enhancing ox-LDL uptake and foam cell formation, linking CD…
DOI: 10.1182/blood.v87.5.2020.2020 -
Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
Probucol treatment in Watanabe heritable hyperlipidemic (WHHL) rabbits markedly prevented progression of aortic atherosclerosis without substantial lowering of plasma cholesterol, likely by inhibiting oxidative modification of LDL and subsequent macrophage foam cell formation.
DOI: 10.1073/pnas.84.16.5928 -
Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation
The study shows that CD36 expression is transiently upregulated during in vitro differentiation of human peripheral blood monocytes into macrophages, with functional cell-surface CD36 capable of thrombospondin binding and promoting ox-LDL uptake and foam cell formation, an effec…
DOI: 10.1182/blood.v87.5.2020.bloodjournal8752020 -
Comparative Efficacy of Initial Statin and Ezetimibe Combination versus Statin Monotherapy on Cardiovascular Outcomes in Diabetes Mellitus: A Nationwide Cohort Study
In adults with diabetes, initiating a statin–ezetimibe combination with a lower-intensity statin reduces major adverse cardiovascular events and myocardial infarction compared with high-intensity statin monotherapy, while lowering liver- and diabetes-related hospitalizations in …
DOI: 10.4093/dmj.2024.0482